Crossmark

Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab (DAPHNE): design of a 2-year phase IV trial applying whole-body MRI, MRI-based synthetic CT, and CT

Crossref DOI link: https://doi.org/10.1186/s41927-025-00560-5

Published Online: 2025-10-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Willesen, Simone Tromborg https://orcid.org/0000-0002-8500-4064
Møller, Jakob Møllenbach https://orcid.org/0000-0001-6576-6494
Pedersen, Susanne Juhl https://orcid.org/0000-0002-6500-9263
Østergaard, Mikkel https://orcid.org/0000-0003-3690-467X
Funding

Funding for this research was provided by:

Copenhagen University
License Information

Text and Data Mining valid from 2025-10-16

Version of Record valid from 2025-10-16
More Information

Article History

Received: 5 November 2024

Accepted: 14 August 2025

First Online: 16 October 2025

Declarations

:

: The study is approved by the Danish Ethics Committee through the Clinical Trials Information System (CTIS), EU-CT 2024 -510746-14–00. Signed informed consent to participate in the study is obtained from all participants.

: Not applicable.

: STW none. JMM none. SJP has received grants and contracts from Innovation Fund Denmark and Nordic Bioscience A/S, consulting fees, speaking fees, and/or research support from AbbVie, Novartis, MSD, Pfizer, and UCB. MØ has received research grants from Abbvie, BMS, Merck, Novartis and UCB, and speaker and/or consultancy fees from Abbvie, BMS, Celgene, Eli - Lilly, Galapagos, Gilead, Janssen, MEDAC, Merck, Novartis, Pfizer, Sandoz, and UCB.

Document is current

Any future updates will be listed below